BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37341253)

  • 1. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients.
    Wang Y; Ge W; Xue S; Cui J; Zhang X; Mao T; Xu H; Li S; Ma J; Yue M; Shentu D; Wang L
    IET Syst Biol; 2023 Aug; 17(4):174-186. PubMed ID: 37341253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB.
    Li M; Nurzat Y; Huang H; Min P; Zhang X
    Front Genet; 2023; 14():1028044. PubMed ID: 36816017
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
    Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
    Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of cuproptosis-related long noncoding RNA for predicting prognostic and diagnostic value and immune landscape in colorectal adenocarcinoma.
    Liu S; Zhang S; Liu Y; Yang X; Zheng G
    Hum Genomics; 2023 Mar; 17(1):22. PubMed ID: 36915193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Xu C; Chen A; Mao C; Cui B
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
    Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
    Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer.
    Yao HF; Xu DP; Zheng JH; Xu Y; Jia QY; Zhu YH; Yang J; He RZ; Ma D; Yang MW; Fu XL; Liu DJ; Huo YM; Yang JY; Zhang JF
    Apoptosis; 2023 Aug; 28(7-8):1090-1112. PubMed ID: 37079192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
    Liu L; Wang Q; Zhou JY; Zhang B
    J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
    Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
    BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer.
    Jiang W; Du Y; Zhang W; Zhou W
    Can J Gastroenterol Hepatol; 2022; 2022():4661929. PubMed ID: 36406148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
    Xu X; Liang JH; Xu QC; Yin XY
    Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.